Enovis Corporation (NYSE:ENOV) Shares Acquired by Bernzott Capital Advisors

Bernzott Capital Advisors boosted its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 13.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 158,175 shares of the company's stock after purchasing an additional 18,365 shares during the quarter. Enovis makes up 3.0% of Bernzott Capital Advisors' holdings, making the stock its 17th largest position. Bernzott Capital Advisors owned about 0.28% of Enovis worth $6,044,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after acquiring an additional 75,348 shares in the last quarter. DAVENPORT & Co LLC lifted its position in shares of Enovis by 10.4% in the first quarter. DAVENPORT & Co LLC now owns 3,071,985 shares of the company's stock valued at $116,489,000 after acquiring an additional 289,644 shares in the last quarter. Boston Partners lifted its position in shares of Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock valued at $46,034,000 after acquiring an additional 223,816 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Enovis by 25.0% in the fourth quarter. Royal Bank of Canada now owns 707,361 shares of the company's stock valued at $31,038,000 after acquiring an additional 141,517 shares in the last quarter. Finally, Artemis Investment Management LLP lifted its position in shares of Enovis by 4.5% in the first quarter. Artemis Investment Management LLP now owns 696,118 shares of the company's stock valued at $26,599,000 after acquiring an additional 30,250 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ENOV shares. JMP Securities lowered their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Needham & Company LLC lowered their price objective on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group reduced their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Evercore ISI reduced their price target on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $55.60.

Enovis Trading Down 0.1%

NYSE:ENOV traded down $0.04 on Monday, reaching $26.25. The company's stock had a trading volume of 569,253 shares, compared to its average volume of 931,297. Enovis Corporation has a 12-month low of $25.98 and a 12-month high of $49.83. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -1.88 and a beta of 1.70. The stock has a 50 day moving average price of $32.61 and a 200 day moving average price of $37.10.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. During the same period in the previous year, the firm posted $0.50 earnings per share. The company's revenue was up 8.2% on a year-over-year basis. On average, equities analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.